FOXP2 CRISPR Activation Plasmid (h): sc-417494-ACT

FOXP2 encodes a forkhead box transcription factor that orchestrates gene regulatory programs required for neuronal differentiation, neurite outgrowth, and synaptic plasticity, with prominent roles in cortico-striatal and cerebellar circuits involved in motor learning and vocalization. As a DNA-binding regulator, FOXP2 modulates transcriptional networks controlling chromatin state, RNA processing, and activity-dependent signaling that shape neurodevelopmental trajectories. Genetic variation or altered FOXP2 dosage has been linked to speech and language impairment and broader neurodevelopmental phenotypes, making it a useful node for dissecting transcriptional control of neural circuit function. Experimental modulation of FOXP2 supports studies of transcription-factor-driven lineage specification and downstream pathway remodeling in human cellular models.

FOXP2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FOXP2 expression without altering the underlying DNA sequence.

FOXP2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FOXP2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FOXP2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous FOXP2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FOXP2 locus and enabling the study of FOXP2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of FOXP2 pathway restoration in tumor cells with silenced or reduced FOXP2 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.